Epigenetic quantification of tumor-infiltrating T-lymphocytes

Epigenetics

Volumn 6, Issue 2, 2011, Pages 236-246

  Sehouli, Jalid ^a   Loddenkemper, Christoph ^b   Cornu, Tatjana ^c   Schwachula, Tim ^c   Hoffmüller, Ulrich ^c   Grützkau, Andreas ^d   Lohneis, Philipp ^e   Dickhaus, Thorsten ^f   Gröne, Jörn ^a   Kruschewski, Martin ^a   Mustea, Alexander ^g   Turbachova, Ivana ^c   Baron, Udo ^c   Olek, Sven ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c EPIONTIS GMBH   (Germany)

^d DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^e Institut fur Pathologie   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

DNA methylation; Epigenetic immunophenotyping; Regulatory T cells; T lymphocytes; Tumor immunology

Indexed keywords

ACCURACY; ARTICLE; BLOOD ANALYSIS; BRONCHUS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; EPIGENETICS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; MALE; OVARY CANCER; PARAMETER; PROGNOSIS; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 79951494263     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.2.13755     Document Type: Article

References (42)

1. Guiot C, Degiorgis PG, Delsanto PP, Gabriele P, Deisboeck TS. Does tumor growth follow a "universal law"? J Theor Biol 2003; 225:147-51.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8.
3. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60.
4. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206:347-9.
5. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11.
6. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004; 200:1581-92.
7. Baier PK, Wimmenauer S, Hirsch T, von Specht BU, von Kleist S, Keller H, et al. Analysis of the T cell receptor variability of tumor-infiltrating lymphocytes in colorectal carcinomas. Tumour Biol 1998; 19:205-12.
8. + ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52:423-8.
9. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 02:18538-43.
10. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13.
11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4.
12. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003; 3:189-98.
13. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
14. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
15. Rudensky AY, Gavin M, Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006; 126:253-6.
16. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766-70.
17. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-64.
18. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-8.
19. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
20. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107:2866-72.
21. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-8.
22. + T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007; 13: 2075-81.
23. - T cells. J Clin Invest 2003; 112:1437-43.
24. + regulatory T cells at the single-cell level. Eur J Immunol 2005; 35:1681-91.
25. Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007; 37:21-3.
26. Curiel TJ. Regulatory T-cell development: is Foxp3 the decider? Nat Med 2007; 13:250-3.
27. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20:241-6.
28. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006; 49:411-24.
29. Bock C, Paulsen M, Tierling S, Mikeska T, Lengauer T, Walter J. CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats and predicted DNA structure. PLoS Genet 2006; 2:26.
30. Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, et al. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol 2009; 16:564-71.
31. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996; 24:5064-6.
32. Rapko S, Baron U, Hoffmuller U, Model F, Wolfe L, Olek S. DNA methylation analysis as novel tool for quality control in regenerative medicine. Tissue Eng 2007; 13:2271-80.
33. Baron U, Turbachova I, Hellwag A, Eckhardt F, Berlin K, Hoffmuller U, et al. DNA methylation analysis as a tool for cell typing. Epigenetics 2006; 1:55-60.
34. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37:2378-89.
35. Stockis J, Fink W, Francois V, Connerotte T, de Smet C, Knoops L, et al. Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol 2009; 39:869-82.
36. Lewin J, Schmitt AO, Adorjan P, Hildmann T, Piepenbrock C. Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics 2004; 20: 3005-12.
37. Rasmussen R. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, Eds. Rapid cycle real-time PCR, methods and applications. Edition Heidelberg: Springer Press 2001; 21-34.
38. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Statistic Ass 1958; 53:457-63.
39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 1966; 50:163-70.
40. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69:599-608.
41. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51.
42. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67:1883-6.